Acadia Pharmaceuticals (ACAD) Income towards Parent Company: 2009-2025
Historic Income towards Parent Company for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $71.8 million.
- Acadia Pharmaceuticals' Income towards Parent Company rose 119.14% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.33%. This contributed to the annual value of $226.5 million for FY2024, which is 469.20% up from last year.
- As of Q3 2025, Acadia Pharmaceuticals' Income towards Parent Company stood at $71.8 million, which was up 169.26% from $26.7 million recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' Income towards Parent Company registered a high of $143.8 million during Q4 2024, and its lowest value of -$113.1 million during Q1 2022.
- Over the past 3 years, Acadia Pharmaceuticals' median Income towards Parent Company value was $26.7 million (recorded in 2025), while the average stood at $25.7 million.
- Per our database at Business Quant, Acadia Pharmaceuticals' Income towards Parent Company tumbled by 139.49% in 2023 and then skyrocketed by 2,898.20% in 2024.
- Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Income towards Parent Company stood at -$43.1 million in 2021, then grew by 3.29% to -$41.7 million in 2022, then spiked by 209.77% to $45.7 million in 2023, then skyrocketed by 214.23% to $143.8 million in 2024, then surged by 119.14% to $71.8 million in 2025.
- Its Income towards Parent Company stands at $71.8 million for Q3 2025, versus $26.7 million for Q2 2025 and $19.0 million for Q1 2025.